Crinetics (CRNX) CFO receives 50,000 options and 32,000 RSUs in new grant

Rhea-AI Filing Summary

Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported new equity awards. On February 23, 2026, Schilke was granted stock options for 50,000 shares of Crinetics common stock at an exercise price of $0.0000 per share, held as direct ownership.

He also received 32,000 shares of common stock as a grant described in the footnotes as restricted stock units. These units vest 25% annually beginning on March 1, 2027. Following the grant, Schilke directly owned 84,834 shares of common stock, which includes 834 shares acquired under the company’s Employee Stock Purchase Plan.

The stock options vest and become exercisable in 48 equal monthly installments starting from the vesting commencement date of February 23, 2026, spreading the vesting over four years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schilke Tobin

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		A		32,000	A	$0(1)	84,834(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.79	02/23/2026		A		50,000		(3)	02/23/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.

2. Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.

3. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

Remarks:

	/s/ Tobin Schilke	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CRNX CFO Tobin Schilke report?

Tobin Schilke reported acquiring 50,000 stock options and 32,000 restricted stock units in Crinetics Pharmaceuticals. Both awards were granted on February 23, 2026, at a price of $0.0000 per share, reflecting equity-based compensation rather than open-market purchases.

How many Crinetics (CRNX) stock options were granted to the CFO?

The CFO received stock options covering 50,000 shares of Crinetics common stock. These options vest in 48 equal monthly installments starting February 23, 2026, spreading the exercisability over four years and aligning the award with longer-term service at the company.

What are the vesting terms of the CRNX restricted stock units granted to the CFO?

The 32,000 restricted stock units granted to the CFO vest 25% each year beginning March 1, 2027. This schedule means the award vests in four annual installments, linking the realization of full ownership to continued employment over several years.

How many CRNX common shares does the CFO own after these grants?

After the reported transactions, the CFO directly owned 84,834 shares of Crinetics common stock. This total includes 834 shares acquired under the company’s Employee Stock Purchase Plan, as disclosed in the footnotes accompanying the insider transaction report.

Were the CRNX insider awards open-market purchases or equity grants?

The awards were equity grants, not open-market purchases. The Form 4 shows a transaction code "A" for grant or award acquisition, a price of $0.0000 per share, and describes the awards as stock options and restricted stock units with specified vesting schedules.

What does the Employee Stock Purchase Plan note mean for CRNX CFO ownership?

The filing notes that the CFO’s holdings include 834 shares acquired under Crinetics’ Employee Stock Purchase Plan. This clarifies that a portion of his 84,834 directly owned shares comes from employee share purchases rather than option exercises or restricted stock unit vesting.